Clinical trial
Effects of Cilostazol on VEGF and Oxidative Stress Biomarkers in Hemodialysis…
NCT00431249 · Tungs' Taichung Metroharbour Hospital, Other · Completed
Key facts
| NCT number | NCT00431249 |
|---|---|
| Title | Effects of Cilostazol on VEGF and Oxidative Stress Biomarkers in Hemodialysis Patients With Peripheral Vascular Disease |
| Official title | Effects of Cilostazol on Vascular Endothelial Growth Factor , Inflammatory and Oxidative Stress Biomarkers in Hemodialysis Patients With Peripheral Vascular Disease. |
| Lead sponsor | Tungs' Taichung Metroharbour Hospital, Other |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Hemodialysis Patients, Peripheral Vascular Disease |
| Intervention type | Drug |
| Interventions | Cilostazol |
| Enrollment | 40 |
| Start date | Feb 1, 2007 |
| Primary completion | Apr 1, 2008 |
| Completion | Apr 1, 2008 |
| First posted | Feb 5, 2007 |
| Last update posted | May 12, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: